Lamictal is the private name under which the anti-epileptic and also anti-convulsant drug named lamotrigine is sold by the world renowned pharmaceutical enterprise, Glaxo SmithKline. The main therapeutic uses of this medication are the treatment of epilepsy along with seizures in adults as well as small children, treatment of bipolar disorder as well as the depression associated with it and also for the management of migraines, cluster headaches and also neuropathic pains. According to the pharmacological reports, this drug acts through inhibiting the voltage very sensitive sodium channels within the human body which in turn stabilizes the neuronal membrane and alters the release of amino acids.

Lamictal was released for the first time around December, 1994, and quickly received approval for the treatment of partial seizures. Four years after in August, 1998, the latest form of this medication was released as chewable and dispersible tablets and in the same year it was appropriate for being used as the single treatment which could be prescribed for the therapy for partial seizures in adults. That it was in January, 2003, who’s received approval for being prescribed to children as young as Two years of age and in the four week period of June the same twelve months, its effectiveness against the bipolar disorder appeared to be clinically accepted.